News

Members of Horizon Europe mission assemblies announced

Published on | 5 years ago

Programmes Horizon 2020

The members of the Horizon Europe mission assemblies were announced. These mission assemblies will assist the Horizon Europe mission board members.  

  • Members of the mission assembly for adaptation to climate change, including societal transformation: 22 members
  • Members of the mission assembly for cancer: 25 members
  • Members of the mission assembly for healthy oceans, seas, coastal and inland waters: 27 members
  • Members of the mission assembly for climate-neutral and smart cities: 30 members
  • Members of the mission assembly for soil health and food: 22 members

List published by European Commission

Related news articles

Members of Horizon Europe mission boards announced

Horizon WG - Call for Missions Boards members

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1589 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.